Biomarck initiates Phase 2 Clinical study for NSCLC

Biomarck Pharmaceuticals affirmed initiation of Phase 2 Clinical study in advanced NSCLC.  The study is meant to compare  standard of Care Therapy alone to SOC plus BIO-11006. BIO-11006 is a novel patented peptide that inhibits the MARCKS protein. Phosphorylation of the MARCKS protein has been shown to stimulate cell division and movement. In the case of NSCLC this refers to inhibition of cancer cell division and movement.

Dr. Brian Dickson, Biomarck’s Chief Executive Officer said “Although advances have been made recently in the treatment of advanced NSCLC especially with immunotherapy, the five-year survival rate remains disappointingly low. These immunotherapeutic agents have significant side effects and quality of life remains a critical issue to both patients and their treating oncologists. Animal studies have shown the ability of BIO-11006 to reduce primary tumor size, prevent the development of secondary tumors and act synergistically with other chemotherapeutic agents.”